BRCA1 and ovarian carcinoma: In a clinical cohort of ovarian cancer, epigenetic inactivation of BRCA1 was linked to a better response to cisplatin treatment and increased overall survival, suggesting that BRCA1 methylation affects the efficacy of cisplatin therapy and hence, the clinical outcome in this type of tumor [72].